CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis-Reference-Cited by-同舟云学术

CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis

Published:2022-04 Issue:4 Volume:12 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Jin An‐Li¹,Zhang Chun‐Yan¹²,Zheng Wen‐Jing³⁴,Xian Jing‐Rong¹,Yang Wen‐Jing¹,Liu Te¹⁵,Chen Wei¹,Li Tong¹,Wang Bei‐Li¹²⁶^ORCID,Pan Bai‐Shen¹⁶,Li Qian¹⁶,Cheng Jian‐Wen³,Wang Peng‐Xiang³,Hu Bo³,Zhou Jian³,Fan Jia³,Yang Xin‐Rong³^ORCID,Guo Wei¹⁷²⁶^ORCID

Affiliation:

1. Department of Laboratory Medicine Zhongshan Hospital Fudan University Shanghai P. R. China

2. Department of Laboratory Medicine Xiamen Branch Zhongshan Hospital Fudan University Xiamen P. R. China

3. Department of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Key Laboratory of Carcinogenesis and Cancer Invasion Ministry of Education Shanghai P. R. China

4. Department of Hepatobiliary Surgery Shenzhen Key Laboratory Guangdong Provincial Key Laboratory of Regional Immunity and Diseases International Cancer Center Shenzhen University General Hospital Shenzhen University Clinical Medical Academy Shenzhen University Shenzhen Guangdong P.R. China

5. Shanghai Geriatric Institute of Chinese Medicine Shanghai University of Traditional Chinese Medicine Shanghai P. R. China

6. Department of Laboratory Medicine Wusong Branch Zhongshan Hospital Fudan University Shanghai P. R. China

7. Cancer Center Zhongshan Hospital Fudan University Shanghai P. R. China

Funder

National Natural Science Foundation of China

Sanming Project of Medicine in Shenzhen

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.794